HIF and oxygen sensing; as important to life as the air we breathe?

Annals of Medicine

Volumn 35, Issue 3, 2003, Pages 183-190

  Wiesener, Michael S ^a   Maxwell, Patrick H ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Erythropoietin; HIF 2 ; Hydroxylation; Hypoxia; Ischemia; Transcription factor; VEGF; VHL

Indexed keywords

6 PHOSPHOFRUCTOKINASE ISOENZYME L; CARDIAC AGENT; ENOLASE; ERYTHROPOIETIN; FG 0041; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE; GLUCOSE TRANSPORTER; HEXOKINASE; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; OXYGEN; OXYGENASE; PEPTIDE DERIVATIVE; PEPTIDE PR39; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN DERIVATIVE; PROTEIN INHIBITOR; PROTEIN SUBUNIT; PROTEIN VP16; PYRUVATE KINASE; RECOMBINANT ERYTHROPOIETIN; SOMATOMEDIN B; TRANSCRIPTION FACTOR; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRIOSEPHOSPHATE ISOMERASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULTHOOD; ANGIOGENESIS; ANTIBODY LABELING; BIOSENSOR; BLOOD VESSEL TONE; CANCER; CANCER INHIBITION; CANCER MODEL; CARCINOGENESIS; CELL FUNCTION; CELL GROWTH; CELL HYPOXIA; CELL METABOLISM; CELL TYPE; CELL VIABILITY; CLINICAL MEDICINE; DEVELOPMENT; DISEASE ASSOCIATION; EMBRYO DEVELOPMENT; GENE ACTIVATION; GENE EXPRESSION; GENETICS; GLUCOSE TRANSPORT; GLYCOLYSIS; HEART INFARCTION; HUMAN; IRON TRANSPORT; KIDNEY CARCINOMA; KNOCKOUT MOUSE; LIMB ISCHEMIA; MOLECULAR WEIGHT; MOTOR NEURON DISEASE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OXYGEN SUPPLY; OXYGEN TENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYCYTHEMIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RESPIRATORY DISTRESS; SHORT SURVEY; TISSUE DISTRIBUTION;

ADULT; ANIMALS; ANOXIA; DNA-BINDING PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MICE; MIXED FUNCTION OXYGENASES; MODELS, ANIMAL; NEOPLASMS; NUCLEAR PROTEINS; OXYGEN; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 0038121969     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/0785389031000458233     Document Type: Short Survey

References (71)

1. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 1993; 44: 1149-62.
2. Bachmann S, Le Hir M, Eckardt K-U. Colocalization of erythropoietin mRNA and ecto-5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 1993; 41: 335-41.
3. Goldberg MA, Glass GA, Cunningham JM, Bunn HF. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci USA 1987; 84: 7972-6.
4. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230-7.
5. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11: 72-82.
6. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia- inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997; 94: 4273-8.
7. O'Rourke JF, Tian YM, Ratcliffe PJ, Pugh CW. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1alpha. J Biol Chem 1999; 274: 2060-71.
8. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998; 92: 2260-8.
9. 2 sensing. Science 2001; 292: 464-8.
10. 2-regulated prolyl hydroxylation. Science 2001; 292: 468-72.
11. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001; 20: 5197-206.
12. Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-5.
13. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, et al. C. elegans EGL-9 and Mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107: 43-54.
14. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that mod fy HIF. Science 2001; 294: 1337-40.
15. Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 2002; 417: 975-8.
16. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG, Jr., Pavletich NP. Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science 2002; 296: 1886-9.
17. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 1996; 93: 12969-73.
18. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002; 295: 858-61.
19. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15: 2675-86.
20. Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to gactor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 2002; 277: 26351-5.
21. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002; 16: 1466-71.
22. Lee C, Kim SJ, Jeong DG, Lee SM, Ryu SE. Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and VHL. J Biol Chem 2002; 278: 7558-63.
23. Dann CE, III, Bruick RK, Deisenhofer J. Structure of factor-inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway. Proc Natl Acad Sci USA 2002; 99: 15351-6.
24. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002; 111: 709-20.
25. 2-regulated gene expression. FASEB J 2002; 16: 1151-62.
26. Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 1998; 7: 205-13.
27. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001; 414: 550-4.
28. Wax SD, Rosenfield CL, Taubman MB. Identification of a novel growth factor-responsive gene in vascular smooth muscle cells. J Biol Chem 1994; 269: 13041-7.
29. Madden SL, Galella EA, Riley D, Bertelsen AH, Beaudry GA. Induction of cell growth regulatory genes by p53. Cancer Res 1996; 56: 5384-90.
30. Oehme F, Ellinghaus P, Kolkhof P, Smith TJ, Ramakrishnan S, Hutter J, et al. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem Biophys Res Commun 2002; 296: 343.
31. Jiang H, Guo R, Powell-Coffman JA. The Caenorhabditis elegans hif-1 gene encodes a bHLH-PAS protein that is required for adaptation to hypoxia. Proc Natl Acad Sci USA 2001; 98: 7916-21.
32. Lavista-Llanos S, Centanin L, Irisarri M, Russo DM, Gleadle JM, Bocca SN, et al. Control of the hypoxic response in drosophila melanogaster by the basic helix-loop-helix PAS protein similar. Mol Cell Biol 2002; 22: 6842-53.
33. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94: 8104-9.
34. Carmeliet P, Dor Y, Herbert J-M, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation, and tumor angiogenesis. Nature 1998; 394: 435-9.
35. Wiesener MS, Münchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001; 61: 5215-22.
36. Ivan M, Kaelin WG. The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 2001; 11: 27-34.
37. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002; 1: 459-68.
38. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG, Jr.. Inhibition of HIF is necessary for tumor suppression by the von Hippel- Lindau protein. Cancer Cell 2002; 1: 237-46.
39. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002; 1: 247-55.
40. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, et al. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 2002; 62: 3803-11.
41. Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 2002; 62: 3014-9.
42. Gnarra JR, Ward JM, Porter FD, Wagner JR, Devor DE, Grinberg A, et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 1997; 94: 9102-7.
43. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998; 17: 3005-15.
44. 2 homeostasis by hypoxia- inducible factor 1 alpha. Genes Dev 1998; 12: 149-62.
45. Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 1998; 12: 3320-4.
46. Peng J, Zhang L, Drysdale L, Fong GH. The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc Natl Acad Sci USA 2000; 97: 8386-91.
47. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997; 386: 403-7.
48. Kotch LE, Iyer NV, Laughner E, Semenza GL. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 1999; 209: 254-67.
49. Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 2002; 8: 702-10.
50. Schipani E, Ryan HE, Didrickson S, Kobayashi T, Knight M, Johnson RS. Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev 2001; 15: 2865-76.
51. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest 1999; 103: 691-6.
52. Kline DD, Peng YJ, Manalo DJ, Semenza GL, Prabhakar NR. Defective carotid body function and impaired ventilatory responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1 alpha. Proc Natl Acad Sci USA 2002; 99: 821-6.
53. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001; 28: 131-8.
54. Kojima H, Gu H, Nomura S, Caldwell CC, Kobata T, Carmeliet P, et al. Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha-deficient chimeric mice. Proc Natl Acad Sci USA 2002; 99: 2170-4.
55. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002; 32: 614-21.
56. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 2001; 15: 2445-53.
57. Wiesener MS, Jürgensen J-S, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, et al. Widespread, hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 2002; 17: 271-3.
58. Rosenberger C, Mandriota S, Jürgensen JS, Wiesener MS, Horstrup JH, Frei U, et al. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002; 13: 1721-32.
59. 2 distribution in the living tissue. Kidney Int 1997; 51: 372-80.
60. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000; 342: 626-33.
61. Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Opbthalmol Vis Sci 1999; 40: 182-9.
62. Bergeron M, Gidday JM, Yu AY, Semenza GL, Ferriero DM, Sharp FR. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain. Ann Neurol 2000; 48: 285-96.
63. Elson DA, Thurston G, Huang LE, Ginzinger DG McDonald DM, Johnson RS, et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev 2001; 15: 2520-32.
64. Ivan M, Haberberger T, Gervasi DC, Michelson KS, Gunzler V, Kondo K, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 2002; 99: 13459-64.
65. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C, et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000; 102: 2255-61.
66. Shyu KG, Wang MT, Wang BW, Chang CC, Leu JG, Kuan P, et al. Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 2002; 54: 576-83.
67. Li J, Post M, Volk R, Gao Y, Li M, Metais C, et al. PR39, a peptide regulator of angiogenesis. Nat Med 2000; 6: 49-55.
68. Nwogu JI, Geenen D, Bean M, Brenner MC, Huang X, Buttrick PM. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 2001; 104: 2216-21.
69. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker H, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002; 62: 4316-24.
70. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000; 6: 1335-40.
71. Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 1999; 100: 547-52.